Grauer G F, Greco D S, Behrend E N, Fettman M J, Mani I, Getzy D M, Reinhart G A
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523, USA.
Am J Vet Res. 1996 Jun;57(6):948-56.
To evaluate the protective effects of dietary n-3 fatty acid supplementation versus treatment with a thromboxane synthetase inhibitor (TXSI) in dogs given high-dose gentamicin.
Clinicopathologic and renal histopathologic changes induced by gentamicin (10 mg/kg of body weight, IM, q 8 h, for 8 days) were compared in dogs fed an n-3 fatty acid-supplemented diet containing a fatty acid ratio of 5.7:1 (n-6:n-3), dogs treated with CGS 12970 (a specific TXSI given at 30 mg/kg, PO, q 8 h, beginning 2 days prior to gentamicin administration), and control dogs. The TXSI-treated and control dogs were fed a diet with a fatty acid ratio of 51.5:1 (n-6:n-3). Both diets were fed beginning 42 days prior to and during the 8-day course of gentamicin administration.
Eighteen 6-month-old male Beagles, 6 in each group.
After 8 days of gentamicin administration, differences existed among groups. Compared with n-3-supplemented and control dogs. TXSI-treated dogs had higher creatinine clearance. Both TXSI-treated and n-3-supplemented dogs had higher urinary prostaglandin E2 and E3 (PGE2/3) and 6-keto prostaglandin F1a (PGF1a) excretion, compared with control dogs. Urinary thromboxane B2 (TXB2) excretion was higher in n-3-supplemented and control dogs, compared with TXSI-treated dogs. Urine PGE2/3-to-TXB2 and PGF(in)-to-TXB2, ratios were increased in TXSI-treated dogs, compared with n-3-supplemented and control dogs, and these ratios were increased in n-3-supplemented dogs, compared with control dogs. In addition, TXSI-treated and n-3-supplemented dogs had lower urinary protein excretion, compared with control dogs. Proximal tubular necrosis was less severe in TXSI-treated dogs, compared with control dogs.
Treatment with CGS 12970 prior to and during gentamicin administration prevented increases in urinary TXB2 excretion and reduced nephrotoxicosis.
Increased renal production/excretion of thromboxane is important in the pathogenesis of gentamicin-induced nephrotoxicosis.
评估在给予高剂量庆大霉素的犬中,饮食补充n-3脂肪酸与用血栓素合成酶抑制剂(TXSI)治疗的保护作用。
比较在喂食脂肪酸比例为5.7:1(n-6:n-3)的n-3脂肪酸补充饮食的犬、用CGS 12970(一种特定的TXSI,在庆大霉素给药前2天开始,以30mg/kg口服,每8小时一次)治疗的犬和对照犬中,由庆大霉素(10mg/kg体重,肌肉注射,每8小时一次,共8天)诱导的临床病理和肾脏组织病理学变化。接受TXSI治疗的犬和对照犬喂食脂肪酸比例为51.5:1(n-6:n-3)的饮食。两种饮食在庆大霉素给药的8天疗程之前42天开始并在给药期间喂食。
18只6个月大的雄性比格犬,每组6只。
庆大霉素给药8天后,各组之间存在差异。与补充n-3脂肪酸的犬和对照犬相比,接受TXSI治疗的犬肌酐清除率更高。与对照犬相比,接受TXSI治疗的犬和补充n-3脂肪酸的犬尿前列腺素E2和E3(PGE2/3)以及6-酮前列腺素F1α(PGF1α)排泄更高。与接受TXSI治疗的犬相比,补充n-3脂肪酸的犬和对照犬尿血栓素B2(TXB2)排泄更高。与补充n-3脂肪酸的犬和对照犬相比,接受TXSI治疗的犬尿PGE2/3与TXB2以及PGF(in)与TXB2的比率增加,并且与对照犬相比,补充n-3脂肪酸的犬这些比率增加。此外,与对照犬相比,接受TXSI治疗的犬和补充n-3脂肪酸的犬尿蛋白排泄更低。与对照犬相比,接受TXSI治疗的犬近端肾小管坏死较轻。
在庆大霉素给药之前和期间用CGS 12970治疗可防止尿TXB2排泄增加并减轻肾毒性。
血栓素的肾脏产生/排泄增加在庆大霉素诱导的肾毒性发病机制中很重要。